38 related articles for article (PubMed ID: 19704336)
1. A phase I, open-label dose-escalation study of continuous treatment with BIBF 1120 in combination with paclitaxel and carboplatin as first-line treatment in patients with advanced non-small-cell lung cancer.
Doebele RC; Conkling P; Traynor AM; Otterson GA; Zhao Y; Wind S; Stopfer P; Kaiser R; Camidge DR
Ann Oncol; 2012 Aug; 23(8):2094-2102. PubMed ID: 22345119
[TBL] [Abstract][Full Text] [Related]
2. A phase 1 study evaluating the pharmacokinetics and preliminary efficacy of veliparib (ABT-888) in combination with carboplatin/paclitaxel in Japanese subjects with non-small cell lung cancer (NSCLC).
Mizugaki H; Yamamoto N; Nokihara H; Fujiwara Y; Horinouchi H; Kanda S; Kitazono S; Yagishita S; Xiong H; Qian J; Hashiba H; Shepherd SP; Giranda V; Tamura T
Cancer Chemother Pharmacol; 2015 Nov; 76(5):1063-72. PubMed ID: 26433581
[TBL] [Abstract][Full Text] [Related]
3. Figitumumab combined with carboplatin and paclitaxel in treatment-naïve Japanese patients with advanced non-small cell lung cancer.
Goto Y; Sekine I; Tanioka M; Shibata T; Tanai C; Asahina H; Nokihara H; Yamamoto N; Kunitoh H; Ohe Y; Kikkawa H; Ohki E; Tamura T
Invest New Drugs; 2012 Aug; 30(4):1548-56. PubMed ID: 21748299
[TBL] [Abstract][Full Text] [Related]
4. Population pharmacokinetic and pharmacodynamic analysis to support treatment optimization of combination chemotherapy with indisulam and carboplatin.
Zandvliet AS; Schellens JH; Dittrich C; Wanders J; Beijnen JH; Huitema AD
Br J Clin Pharmacol; 2008 Oct; 66(4):485-97. PubMed ID: 18637887
[TBL] [Abstract][Full Text] [Related]
5. Unlocking the potential of RNA-based therapeutics in the lung: current status and future directions.
Man HSJ; Moosa VA; Singh A; Wu L; Granton JT; Juvet SC; Hoang CD; de Perrot M
Front Genet; 2023; 14():1281538. PubMed ID: 38075698
[TBL] [Abstract][Full Text] [Related]
6. A Brief Introduction to Current Cancer Gene Therapy.
Kobelt D; Pahle J; Walther W
Methods Mol Biol; 2022; 2521():1-21. PubMed ID: 35732990
[TBL] [Abstract][Full Text] [Related]
7. Effect of NF-κB p65 antisense oligodeoxynucleotide on transdifferentiation of normal human lens epithelial cells induced by transforming growth factor-β2.
Liu C; Wu XL; Wu XY; Zhang ZH; Liu XH
Int J Ophthalmol; 2016; 9(1):29-32. PubMed ID: 26949606
[TBL] [Abstract][Full Text] [Related]
8. Translational Approaches towards Cancer Gene Therapy: Hurdles and Hopes.
Barar J; Omidi Y
Bioimpacts; 2012; 2(3):127-43. PubMed ID: 23678451
[TBL] [Abstract][Full Text] [Related]
9. Effect of antisense oligodeoxynucleotide targeted against NF-κB/P65 on cell proliferation and tumorigenesis of gastric cancer.
Li Q; Gao Y; Xu ZG; Jiang H; Yu YY; Zhu ZG
Clin Exp Med; 2013 Feb; 13(1):11-9. PubMed ID: 22234797
[TBL] [Abstract][Full Text] [Related]
10. Restoring dystrophin expression in duchenne muscular dystrophy muscle progress in exon skipping and stop codon read through.
Hoffman EP; Bronson A; Levin AA; Takeda S; Yokota T; Baudy AR; Connor EM
Am J Pathol; 2011 Jul; 179(1):12-22. PubMed ID: 21703390
[TBL] [Abstract][Full Text] [Related]
11. Oligonucleotide therapeutic approaches for Huntington disease.
Sah DW; Aronin N
J Clin Invest; 2011 Feb; 121(2):500-7. PubMed ID: 21285523
[TBL] [Abstract][Full Text] [Related]
12. A phase I/randomized phase II, non-comparative, multicenter, open label trial of CP-547,632 in combination with paclitaxel and carboplatin or paclitaxel and carboplatin alone as first-line treatment for advanced non-small cell lung cancer (NSCLC).
Cohen RB; Langer CJ; Simon GR; Eisenberg PD; Hainsworth JD; Madajewicz S; Cosgriff TM; Pierce K; Xu H; Liau K; Healey D
Cancer Chemother Pharmacol; 2007 Jun; 60(1):81-9. PubMed ID: 17031646
[TBL] [Abstract][Full Text] [Related]
13. Induction paclitaxel and carboplatin followed by concurrent chemoradiotherapy in patients with unresectable, locally advanced non-small cell lung carcinoma: report of Fox Chase Cancer Center study 94-001.
Langer CJ; Movsas B; Hudes R; Schol J; Keenan E; Kilpatrick D; Yeung C; Curran W
Semin Oncol; 1997 Aug; 24(4 Suppl 12):S12-89-S12-95. PubMed ID: 9331129
[TBL] [Abstract][Full Text] [Related]
14. High-dose therapy with carboplatin and paclitaxel in non-small cell lung cancer.
Socinski MA; Shea TC
Semin Oncol; 1997 Aug; 24(4 Suppl 12):S12-45-S12-51. PubMed ID: 9331121
[TBL] [Abstract][Full Text] [Related]
15. Phase II study of carboplatin-paclitaxel combination chemotherapy in elderly patients with advanced non-small cell lung cancer.
Okamoto I; Moriyama E; Fujii S; Kishi H; Nomura M; Goto E; Kiyofuji C; Imamura F; Mori T; Matsumoto M
Jpn J Clin Oncol; 2005 Apr; 35(4):188-94. PubMed ID: 15845567
[TBL] [Abstract][Full Text] [Related]
16. Phase I study of the c-raf-1 antisense oligonucleotide ISIS 5132 in combination with carboplatin and paclitaxel in patients with previously untreated, advanced non-small cell lung cancer.
Fidias P; Pennell NA; Boral AL; Shapiro GI; Skarin AT; Eder JP; Kwoh TJ; Geary RS; Johnson BE; Lynch TJ; Supko JG
J Thorac Oncol; 2009 Sep; 4(9):1156-62. PubMed ID: 19704336
[TBL] [Abstract][Full Text] [Related]
17. Phase I trial of the matrix metalloproteinase inhibitor marimastat combined with carboplatin and paclitaxel in patients with advanced non-small cell lung cancer.
Goffin JR; Anderson IC; Supko JG; Eder JP; Shapiro GI; Lynch TJ; Shipp M; Johnson BE; Skarin AT
Clin Cancer Res; 2005 May; 11(9):3417-24. PubMed ID: 15867243
[TBL] [Abstract][Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
